Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has promoted Noah Clauser to Chief Financial Officer. Mr. Clauser brings close to 20 years of financial experience to this role and has been with Catabasis for 9 years, most recently as Vice President, Finance.
“Noah has strategically built our financial and operations functions and has been a valuable team member through a critical stage for Catabasis,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “We are looking forward to his expanded role as we approach our potential future transition to a commercial organization.”
“I am excited for this new opportunity as we approach the next stage of our company, with top-line results from the Phase 3 PolarisDMD trial for edasalonexent expected in the fourth quarter of this year,” said Mr. Clauser. “I am looking forward to continuing our work to